title: [Effects of urinastatin on prevention of cisplatin induced nephrotoxicity].
authors.affiliation: Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sasa
authors.forename: A
authors.initials: A
authors.lastname: Hisano
authors.forename: K
authors.initials: K
authors.lastname: Kudo
authors.forename: E
authors.initials: E
authors.lastname: Kuki
authors.forename: M
authors.initials: M
authors.lastname: Miyauchi
authors.forename: T
authors.initials: T
authors.lastname: Kita
authors.forename: Y
authors.initials: Y
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Tode
authors.forename: K
authors.initials: K
authors.lastname: Furuya
authors.forename: I
authors.initials: I
authors.lastname: Nagata
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D007674:Kidney Diseases / Q000517:prevention & control*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D006023:Glycoproteins; D004317:Doxorubicin; D003520:Cyclophosphamide; C028665:urinastatin; D002945:Cisplatin